Home Cart Sign in  
Chemical Structure| 1782970-28-8 Chemical Structure| 1782970-28-8

Structure of PTC-028
CAS No.: 1782970-28-8

Chemical Structure| 1782970-28-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PTC-028 can decrease BMI-1 levels by posttranslational modification.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PTC-028

CAS No. :1782970-28-8
Formula : C19H12F5N5
M.W : 405.32
SMILES Code : FC(C1=CC=C(NC2=NC(N3C4=CC(F)=C(F)C=C4N=C3C)=CN=C2)C=C1)(F)F
MDL No. :MFCD28716152
InChI Key :JEZGPBWIZWPDHP-UHFFFAOYSA-N
Pubchem ID :73427235

Safety of PTC-028

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of PTC-028

Hedgehog

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDS-L cells 3 and 5 µM 4 hours PTC-028 treatment for 4 hours resulted in the near-complete loss of polymerized microtubules Cancer Sci. 2020 Dec;111(12):4336-4347
Ovarian cancer cells (OVCAR4, OV90, CP20) 100 nM to 500 nM 48 hours Evaluate the effect of PTC-028 on cancer cell viability, showing significant dose-dependent decrease in cell viability Mol Cancer Ther. 2018 Jan;17(1):39-49
Fallopian tube epithelial cells (FTE187 and FTE188) 500 nM 48 hours Evaluate the effect of PTC-028 on cell viability, showing minimal effect on normal cells (∼18-30% decrease) Mol Cancer Ther. 2018 Jan;17(1):39-49
Ovarian surface epithelial cells (OSE) 500 nM 48 hours Evaluate the effect of PTC-028 on cell viability, showing minimal effect on normal cells (∼18-30% decrease) Mol Cancer Ther. 2018 Jan;17(1):39-49
AN3CA cells 50 nM 48 hours PTC-028 significantly depleted BMI1 levels and decreased cellular viability by triggering caspase-dependent apoptosis Mol Cancer Ther. 2018 Oct;17(10):2136-2143
CS99 cells 50 nM 48 hours PTC-028 significantly depleted BMI1 levels and decreased cellular viability by triggering caspase-dependent apoptosis Mol Cancer Ther. 2018 Oct;17(10):2136-2143
Ishikawa cells 50 nM 48 hours PTC-028 significantly depleted BMI1 levels and decreased cellular viability by triggering caspase-dependent apoptosis Mol Cancer Ther. 2018 Oct;17(10):2136-2143
VUMC-DIPG10 39.5 nM (IC50) 5 days Inhibition of BMI1 expression significantly inhibits DIPG cell growth Cell Rep. 2020 Oct 20;33(3):108286
SF8628 27.87 nM (IC50) 5 days Inhibition of BMI1 expression significantly inhibits DIPG cell growth Cell Rep. 2020 Oct 20;33(3):108286
BT245 25.1 nM (IC50) 5 days Inhibition of BMI1 expression significantly inhibits DIPG cell growth Cell Rep. 2020 Oct 20;33(3):108286
HSJD-DIPG-007 28.56 nM (IC50) 5 days Inhibition of BMI1 expression significantly inhibits DIPG cell growth Cell Rep. 2020 Oct 20;33(3):108286
SU-DIPG04 25.96 nM (IC50) 5 days Inhibition of BMI1 expression significantly inhibits DIPG cell growth Cell Rep. 2020 Oct 20;33(3):108286
ASCs (CD20−CD3−CD14−CD16−CD19+CD27hiCD38hi) 1.25 µM 6 days To evaluate the effect of PTC-028 on human ASC survival. PTC-028 treatment led to a significant reduction in live ASCs from both healthy donors and Sjögren’s syndrome patients. Clin Transl Immunology. 2023 Oct 4;12(10):e1470
SKM-1 cells 30 nM 72 hours PTC-028 suppressed growth and induced apoptosis in MDS cell lines Cancer Sci. 2020 Dec;111(12):4336-4347

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOG IL-3/GM-TG mice MDS-L/Akaluc xenograft model Oral 12.5 mg/kg Twice a week for 7 weeks PTC-028 significantly inhibited MDS-L cell growth and prolonged mouse survival Cancer Sci. 2020 Dec;111(12):4336-4347
NOG IL-3/GM-TG mice MDS xenograft model Oral 12.5 mg/kg Twice a week for 7 weeks PTC-028 significantly inhibited the growth of MDS-L cells and prolonged the overall survival of recipient mice Cancer Sci. 2020 Dec;111(12):4336-4347
Athymic nude mice BT245-luc2-GFP (H3.3K27M mutant) pontine xenograft model Oral 12.5 mg/kg/day Daily administration, continuous treatment PTC028 treatment significantly prolonged animal survival with a median survival of 33 days (control group 22 days), and increased expression of p16, p21, and GLB1 in tumor tissues Cell Rep. 2020 Oct 20;33(3):108286
Nude mice (NCr-nu) Orthotopic ovarian cancer model Oral 15 mg/kg Twice weekly for 3-4 weeks Evaluate the antitumor activity of PTC-028 in vivo, showing significant reduction in tumor weight (~94% reduction) comparable to standard therapy (cisplatin/paclitaxel) Mol Cancer Ther. 2018 Jan;17(1):39-49
Female athymic nude mice Uterine carcinosarcoma xenograft model Oral 15 mg/kg Twice weekly for two weeks PTC-028 significantly delayed tumor growth and increased tumor doubling time Mol Cancer Ther. 2018 Oct;17(10):2136-2143
Nude mice Rh30 xenograft model Oral gavage 15 mg/kg Twice weekly, until tumor volume reached or exceeded 1500 mm³ To evaluate the effect of PTC-028 on tumor growth in the Rh30 xenograft model. Results showed that PTC-028 treatment significantly delayed tumor growth and was well-tolerated. Mol Oncol. 2021 Aug;15(8):2156-2171
Lyn−/− mice SLE model Oral gavage 15 mg/kg Once daily for 12 days To evaluate the effect of PTC-028 on ASCs in Lyn?/? mice. PTC-028 treatment significantly reduced splenic and bone marrow ASCs and led to a significant decrease in serum IgG3 and anti-DNA IgG. Clin Transl Immunology. 2023 Oct 4;12(10):e1470

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.47mL

0.49mL

0.25mL

12.34mL

2.47mL

1.23mL

24.67mL

4.93mL

2.47mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories